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ABSTRACT 
Background: Endothelial dysfunction and injury are thought to play an important role in 
progression of coronary-artery-disease (CAD).  High-density-lipoprotein from healthy subjects 
(HDLHealthy) has been proposed to exert endothelial anti-apoptotic effects that may represent an 
important anti-atherogenic property of the lipoprotein.  The present study therefore aimed to 
compare effects of HDLCAD and HDLHealthy on activation of endothelial anti- and pro-apoptotic 
pathways and to determine which changes of the lipoprotein are relevant for these processes. 
Methods and Results: HDL was isolated from patients with stable CAD (HDLsCAD), an acute 
coronary syndrome (HDLACS) and healthy subjects.  HDLHealthy induced expression of the 
endothelial anti-apoptotic Bcl-2 protein Bcl-xL and reduced endothelial cell apoptosis in vitro 
and in apoE-deficient-mice in vivo. In contrast, HDLsCAD and HDLACS did not inhibit endothelial 
apoptosis, failed to activate endothelial Bcl-xL and stimulated endothelial pro-apoptotic 
pathways, in particular p38-MAPK-mediated activation of the pro-apoptotic Bcl-2-protein tBid. 
Endothelial anti-apoptotic effects of HDLHealthy were observed after inhibition of endothelial 
nitric-oxide-synthase and after delipidation, but not completely mimicked by apoA-I or 
reconstituted HDL, suggesting an important role of the HDL-proteome. HDL proteomics 
analyses and subsequent validations and functional characterizations suggested a reduced 
clusterin- and increased apoC-III-content of HDLsCAD and HDLACS as mechanisms leading to 
altered effects on endothelial apoptosis. 
Conclusion: The present study demonstrates for the first time that HDLCAD does not activate 
endothelial anti-apoptotic pathways, but rather stimulates potential endothelial pro-apoptotic 
pathways. HDL-proteome remodeling plays an important role for these altered functional 
properties of HDL. These findings provide novel insights into mechanisms leading to altered 
vascular effects of HDL in coronary disease.  
 
Key Words: High-density lipoprotein, apoptosis, proteomics, clusterin, apolipoprotein C-III  
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INTRODUCTION 
Reduced plasma levels of HDL cholesterol are associated with an increased risk of coronary 
artery disease (CAD).
1
 Moreover, in patients with CAD that are treated with statin and have low 
levels of low-density lipoprotein (LDL) cholesterol, reduced HDL cholesterol levels were 
predictive of major cardiovascular events.
2
 Besides promoting reverse cholesterol transport,
3, 4
 
HDL has been demonstrated to exert anti-atherosclerotic effects, including anti-inflammatory 
properties and stimulation of endothelial nitric oxide (NO) production.
5-9
  However, these effects 
of HDL have been observed to be highly heterogenous in patients with CAD or diabetes.
10-12
 
Endothelial dysfunction and injury are thought to contribute importantly to the progression of 
CAD.
13-15
  Experimental studies have indicated that atherosclerotic lesion-prone vascular regions 
are characterized by a high endothelial cell turn-over,
16
 which has been attributed to an increased 
rate of endothelial cell apoptosis. Moreover, superficial atherosclerotic plaque erosion with loss 
of an intact endothelial cell monolayer is observed quite frequently in patients with an acute 
coronary syndrome (ACS) based on pathological
17, 18
 as well as on observations from clinical 
high-resolution intracoronary imaging studies.
19
  In pathological studies of coronary 
atherosclerotic plaque erosion thrombi were observed in direct contact with the intima in areas 
with absent endothelium likely promoting disease progression.
17
  Endothelial cell apoptosis has 
therefore been suggested to contribute importantly to the pathophysiology of coronary disease.
20-
22
 The capacity of HDL to attenuate endothelial cell apoptosis may therefore represent a 
potentially important anti-atherogenic property of HDL.
23-26
 
However, as described above, the vascular effects of HDL can be highly variable in patients with 
cardiovascular disease, a phenomenon referred to as “HDL dysfunction”.10, 12, 27  The present 
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study was therefore designed to compare the effects of HDL from patients with stable CAD or an 
ACS and healthy subjects on endothelial anti-apoptotic and pro-apoptotic signaling pathways.  
Moreover, we aimed to characterize alterations in HDL from patients with CAD that may lead to 
altered functional properties of HDL with respect to activation of endothelial anti-apoptotic and 
pro-apoptotic signaling pathways.   
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METHODS 
An expanded description of the methods is available in Supplementary Methods. 
 
Patient Characteristics.  Patients with stable CAD or an ACS (STEMI or NSTEMI) and 
healthy subjects (without cardiovascular risk factors) were recruited at the University Hospital of 
Zurich.  Exclusion criteria were accompanying infectious, inflammatory or autoimmune 
disorders, advanced kidney or liver failure, diabetes, neoplastic disorders and a history of major 
surgery or trauma within the previous month.  
 
Isolation of High-Density Lipoprotein and HDL-delipidation. HDL was isolated by either 
sequential ultracentrifugation (d=1.063-1.21g/ml) or gel filtration chromatography. For 
proteomics studies and functional studies HDL was delipidated using methanol/chloroform 
extraction.  Detailed description of the methods is provided in Supplementary Methods.  
 
Measurement of Endothelial Cell Apoptosis In Vitro. Endothelial apoptosis was measured by 
FACS analysis with annexin-V-staining or TUNEL assay, as well as using fluorescence 
microscopy with annexin-V-staining. Caspase-3 activity was measured using a colorimetric 
assay. Detailed description of the methods is provided in Supplementary Methods.  
 
Measurement of Endothelial Cell Apoptosis In Vivo using FACS Analysis and Active 
Caspase-3 Staining.  Male apoE(-/-).C57BL/6 mice, aged 12-16 weeks, were used for tail-vein 
injection of HDL (14mg HDL-protein/kg body-weight), following anaesthesia with inhalation of 
isoflurane(3%). Twenty-four hours after the injection of HDL or PBS-buffer, mice were 
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euthanized and the aorta were harvested and immediately digested for FACS analysis of 
endothelial cell apoptosis or fixated for histological staining.  For detailed description of the 
methods, please refer to the Supplementary Methods.  
 
Biochemical Validation of HDL-associated Proteins.  ELISA was used for validation of 
changes in clusterin-(BioVendor R&D, USA) and apoC-III-(AssayPro, USA) content of HDL. 
 
Western Blot analysis. Phosphorylation of Akt at serine residue473, phosphorylation of MAPK-
p38 and expression of Bcl-2, Bcl-xL, tBid, Bak were determined by western blot analysis. Anti-
human phospho-Akt(Ser473), anti-human total Akt, anti-human phospho-p38-MAPK, anti-
human total p38-MAPK were purchased from Cell Signaling Technology. Antibodies against 
human Bcl2, Bcl-xL, tBid and Bak were from Cell Signaling Technology.   
 
Statistical Analysis. All data are expressed as mean±SEM. All analyses were performed with 
SPSS 21.0 (IBM SPSS). Significance was tested using Student’s-t-test and ANOVA with 
Dunnett post-hoc test for multiple comparison
 
analysis. A value of p<0.05 was considered 
statistically significant.  
7 
 
RESULTS 
HDL was isolated from patients with coronary disease (HDLCAD), with either stable CAD 
(HDLsCAD) or an acute coronary syndrome (HDLACS), and age- and gender-matched healthy 
subjects (HDLHealthy). The characteristics of the study population are shown in Table 1.  
 
Effects of HDLHealthy and HDLCAD on endothelial cell apoptosis in vitro and in vivo 
HDLHealthy markedly reduced endothelial cell apoptosis in vitro, whereas in marked contrast, 
HDLsCAD or HDLACS did not limit endothelial apoptosis induced by serum and growth factor 
deprivation (Figures 1A-C,E-F).  Endothelial caspase-3 activity was reduced by HDLHealthy, but 
not after treatment with HDLsCAD or HDLACS (Figure 1D). Similarly, detection of fragmented 
DNA using TUNEL staining showed significantly attenuated endothelial apoptosis by HDLHealthy 
(26.7%±12.0% vs control 41.6%±10.3%, p<0.05), but not HDLsCAD or HDLACS (36.9%±9.1% 
and 32.2%±13.6%, respectively).  Furthermore, HDLHealthy but not HDLsCAD or HDLACS reduced 
endothelial apoptosis induced by another stimulus, i.e. TNF-α, as measured by annexin-V 
staining (Figure 1G) or TUNEL assay (apoptotic endothelial cells after HDLHealthy vs. HDLCAD 
23.02%±14.4% vs. 39.7%±13.7%; p<0.05).   The rate of TNF-α-induced endothelial apoptosis 
was similar as compared to previous studies, such as the study by Spyridopoulos et al.
28
  
reporting 39.3% apoptotic endothelial cells after TNF- exposure.  
 
Moreover, we examined the capacity of HDL to impact on endothelial apoptosis in vivo by 
injecting isolated HDL to apoE-/- mice.  Administration of HDLHealthy (14mg HDL-protein/kg 
body weight) to apoE-/- mice reduced endothelial apoptosis in the aorta (harvested after 24hours) 
while HDLCAD did not reduce endothelial apoptosis as determined by Annexin-V measurement 
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as well as immunofluorescence staining with TUNEL and active caspase-3 assay (Figure 2A-E). 
In these studies, we did not observe a significant difference between the anti-apoptotic capacity 
of HDLsCAD as compared to HDLACS (7.2±3.1% vs 6.3±3.8%; p=0.51).  
 
HDLHealthy reduces endothelial apoptosis after inhibition of endothelial NO-synthase 
Endothelial NO synthase is a potentially important regulator of endothelial apoptosis and effects 
of HDL on eNOS are adversely affected in patients with CAD.
10, 29
 We therefore examined 
whether the effects of HDL on endothelial cell apoptosis are critically dependent on eNOS. 
Notably, inhibition of eNOS-mediated NO production by both, pharmacological inhibition with 
N-nitro-L-arginine methyl ester (L-NAME) and eNOS-specific RNA interference did not prevent 
endothelial anti-apoptotic effects of HDLHealthy (Figure 3A), suggesting that HDL  activates 
endothelial anti-apoptotic pathways independent of eNOS.  
 
Role of protein moiety for endothelial anti-apoptotic capacity of HDLHealthy  
To investigate which alterations of the HDL particle may impair the capacity to limit endothelial 
apoptosis, we examined effects of the HDL protein fraction (delipidated HDL), rHDL, purified 
apoA-I and recombinant apoA-I on endothelial apoptosis.  Interestingly, delipidated HDLHealthy 
exerted a potent endothelial anti-apoptotic activity as measured by annexin-V staining (Figure 
3B). The endothelial anti-apoptotic effects of delipidated HDLHealthy were more profound as 
compared to purified or recombinant apoA-I or rHDL (Figure 3B), suggesting an important role 
of the HDL proteome and its remodeling for altered effects of HDLCAD on endothelial apoptosis. 
Similarly, by using TUNEL staining we observed that HDLHealthy and delipidated HDLHealthy 
significantly reduced the number of apoptotic endothelial cells (22.2%±8.0% and 19.0%±14.1% 
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vs control 37.6±10,2%, p<0.05), that was not observed with apoA-1 or rHDL alone 
(29.0%±8.7% and 25.3%±10.4%, respectively, p=0.11 and p=0.08 vs. control).    
 
Proteomics analysis comparing HDLHealthy and HDLCAD using LC-ESI-MS/MS   
We therefore used a mass spectrometric-based approach to identify changes in HDL-associated 
proteins in coronary disease. The spectral index was used for relative quantification of each 
protein of interest,
30, 31
 as described in detail in the Supplementary Material. 
Based on this approach, we identified 78 HDL-associated proteins with substantial differences in 
their quantitative abundance between HDLHealthy and HDLCAD (Figure 3C, Supplementary Table 
1). We further applied gene ontology analysis to identify proteins that are related to regulation of 
apoptosis (Supplementary Table 2). Based on these analyses two proteins, clusterin and apoC-III, 
were selected for further assessment of their potential relevance in mediating effects of HDL on 
endothelial apoptosis, given their differential abundance in HDLCAD and their potential role in 
regulation of apoptotic processes.  
 
Validation of altered clusterin levels in HDLCAD as compared to HDLHealthy and its 
relevance for endothelial anti-apoptotic effects of HDL  
Proteomics analysis indicated reduced clusterin levels in HDLCAD relative to HDLHealthy (spectral 
index of -0.323) (Supplementary Table 1). An MS/MS fragmentation pattern of a proteotypic 
peptide of clusterin is shown in Figure 4A. To further validate this finding, we quantified 
clusterin in HDLHealthy and HDLCAD isolated by two different methods, i.e. ultracentrifugation and 
gel filtration. Independent of the isolation method, substantially lower clusterin levels were 
detected in HDLsCAD and HDLACS as compared to HDLHealthy (Figure 4B, Table 2).  
10 
 
To further investigate a potential functional role of clusterin in HDL for effects on endothelial 
apoptosis, we pre-incubated HDLHealthy with specific clusterin blocking antibodies (Santa Cruz 
Biotechnology, USA) and supplemented HDLCAD with clusterin. Pre-incubation of HDLHealthy 
with clusterin-blocking antibodies (1:50 or 1:100 dilution), but not with an IgG isotype control, 
reduced endothelial anti-apoptotic effects of HDLHealthy in a dose-dependent manner as measured 
by annexin-V staining (Figure 4C). The presence of the clusterin-blocking antibody decreased 
the capacity of HDLHealthy to reduce endothelial cell apoptosis as measured by caspase-3 activity 
(Figure 4D) and TUNEL staining (apoptotic endothelial cells: 38.2±5.6% versus 23.1±6.2%, 
p<0.05). Similarly, the capacity of HDLHealthy to attenuate TNF-α-induced endothelial apoptosis 
was reduced in the presence of clusterin blocking antibody (Figure 4E). Vice versa, 
supplementation of HDLCAD with purified clusterin increased its endothelial anti-apoptotic 
effects (Figure 4F). Notably, purified clusterin alone had no significant effect on endothelial 
apoptosis, indicating that binding of clusterin to the HDL particle was important for its full 
endothelial anti-apoptotic effects. To further investigate the role of HDL-associated clusterin for 
endothelial anti-apoptotic effects of HDL, we prepared reconstituted HDL with and without 
clusterin. Addition of clusterin to rHDL resulted in a more profound endothelial anti-apoptotic 
effect (Figure 4G), supporting a role of HDL-bound clusterin for endothelial anti-apoptotic 
properties of HDLHealthy. Of note, corresponding amounts of HDL-bound clusterin after 
supplementation of reconstituted HDL or HDLCAD were within a similar range as compared to 
clusterin levels observed in HDLHealthy, further supporting the concept that reduced levels of 
HDL-bound clusterin in HDLCAD impact on the capacity of HDL to limit endothelial apoptosis 
(Supplementary Figure 1A).  
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Increased apoC-III levels in HDLsCAD and HDLACS and relevance for effects of HDL on  
endothelial apoptosis  
Based on the spectral index of the proteomics analysis, levels of apoC-III were increased in 
HDLsCAD and HDLACS as compared to HDLHealthy (spectral index of 0.197) (Supplementary Table 
1). An MS/MS fragmentation pattern of a proteotypic peptide of apoC-III is shown in Figure 5A. 
To further validate this finding we quantified apoC-III in HDLHealthy and HDLCAD isolated by 
either ultracentrifugation or gel filtration. HDLsCAD and HDLACS were enriched with apoC-III as 
compared to HDLHealthy (Figure 5B, Table 2). Pre-incubation of HDLCAD with a specific blocking 
antibody for apoC-III (1:50 dilution), but not with an isotype-control-antibody, improved its 
capacity to reduce endothelial apoptosis, both after serum withdrawal (Figures 5C-F) or TNF-α-
exposure (Figures 5G-I). Similarly, the blocking antibody against apoC-III increased the 
endothelial anti-apoptotic capacity of HDLCAD as measured by TUNEL staining (25.2±5.6% 
versus HDLCAD alone 37.1±6.2%, p<0.05). Conversely, pre-incubation of HDLHealthy with 
purified apoC-III impaired its capacity to attenuate endothelial apoptosis (Figure 5J). The 
corresponding amounts of HDL-bound apoC-III after supplementation of HDLHealthy with apoC-
III were in a similar range as compared to HDL-bound apoC-III levels observed in HDLCAD 
(Supplementary Figure 1B). 
 
HDLHealthy activates the endothelial anti-apoptotic Bcl-2 protein Bcl-xL via PI3K/Akt 
pathway, whereas HDLCAD upregulates the endothelial pro-apoptotic Bcl-2 protein tBid via 
MAPK-p38 – role of HDL-associated clusterin and apoC-III. 
Further assessment of signaling mechanisms involved in effects of HDL on endothelial apoptosis 
showed that the anti-apoptotic capacity of HDLHealthy was mediated via PI3K/Akt, since PI3K 
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inhibition by wortmannin or LY294002 prevented endothelial anti-apoptotic effects of 
HDLHealthy, whereas these anti-apoptotic pathways were not activated by HDLCAD (Figure 6A). 
HDLHealthy phosphorylated endothelial Akt at Ser473, which was not observed using HDLsCAD or 
HDLACS (Supplementary Figure 2A).  
 
Our further analysis of downstream targets of HDL on endothelial apoptotic pathways revealed a 
differential regulation of anti-apoptotic and pro-apoptotic proteins from the Bcl-2 family by 
HDLHealthy and HDLCAD. HDLHealthy activated Bcl-xL, an anti-apoptotic Bcl-2 protein
32, 33
 whereas 
HDLCAD activated tBid, a pro-apoptotic Bcl-2 protein
34, 35
 (Figures 6B and 6C). No significant 
differences were observed on the expression of other Bcl-2 proteins, anti-apoptotic protein Bcl-2 
and pro-apoptotic protein Bak by HDLHealthy and HDLCAD (data not shown). Wortmannin or 
LY294002 inhibited effects of HDLHealthy on Bcl-xL expression (Figure 6D). Notably, pre-
incubation of HDLHealthy with clusterin blocking antibody reduced HDL-dependent 
phosphorylation of Akt at Ser473 (Figure 6E) and impaired upregulation of Bcl-xL expression  
(Figure 6F). These findings indicate that clusterin contributes to effects of HDLHealthy on  
stimulation of PI3K/Akt which in turn modulates endothelial expression of the anti-apoptotic 
Bcl-xL.  
 
Furthermore, assessment of the role of mitogen-activated protein kinase (MAPK) demonstrated 
that HDLCAD increased endothelial phosphorylation of p38-MAPK, whereas HDLHealthy had no 
effect (Figure 7A). Inhibition of HDLCAD induced p38-MAPK-activation using the inhibitor 
SB203580 blocked the increase in endothelial expression of tBid (Figure 7B). Pre-incubation of 
HDLCAD with the specific blocking antibody against apoC-III inhibited the increased 
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phosphorylation of p38 MAPK (Figure 7C) and the increased expression of tBid (Figure 7D). 
These observations suggest that HDL-associated apoC-III stimulates pro-apoptotic signaling by 
phosphorylation of p38-MAPK and upregulation of endothelial expression of pro-apoptotic tBid.  
 
Assessment of clusterin and apoC-III content in other lipoprotein fractions  
The content of clusterin in serum or in the LDL/VLDL fraction was not reduced in patients with 
CAD as compared to healthy subjects (Table 2), whereas clusterin levels were substantially 
lower in HDLCAD  as compared to HDLHealthy isolated by both ultracentrifugation or gel filtration 
methods, compatible with the concept of a reduced binding of clusterin to HDLCAD (Table 2).  
 
The apoC-III content was mainly increased in HDLCAD, but was also to some extent elevated in 
serum and the LDL/VLDL fraction of patients with CAD as compared to healthy subjects using 
both, ultracentrifugation or gel filtration lipoprotein isolation protocols (Table 2). These 
observations suggest a systemic increase of apoC-III levels in patients with CAD. 
 
Role of SR-BI for endothelial anti-apoptotic effects of HDL 
Pre-incubation of endothelial cells with blocking antibody against SR-BI inhibited endothelial 
anti-apoptotic effects of HDLHealthy (Supplementary Figures 3A-B). Further studies on clusterin 
or apoCIII and SR-BI-dependent endothelial binding of HDL are described in the supplementary 
file.  The SR-BI blocking antibody also reduced the anti-apoptotic capacity of rHDL/Clu 
(Supplementary Figure 3A). These observations suggest that the capacity of HDL-associated 
clusterin to reduce endothelial apoptosis is mediated, at least in part, via SR-BI.   
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DISCUSSION 
In the present study we have for the first time compared the effects of HDL from healthy 
subjects and from patients with CAD on endothelial cell anti- and pro-apoptotic signaling 
pathways.  Importantly, while HDLHealthy substantially reduced endothelial cell apoptosis in vitro 
and in vivo, no such effects were observed for HDL from patients with sCAD or ACS.   
 
Of note, our studies revealed differential effects of HDLHealthy and HDLCAD on endothelial anti- 
and pro-apoptotic signaling pathways, in particular on members of the Bcl-2 family of proteins, 
that are critical regulators of apoptosis.  HDLHealthy, but not HDLCAD, activated the endothelial 
anti-apoptotic Bcl-xL pathway.  In contrast, HDLCAD activated endothelial tBid, a pro-apoptotic 
Bcl-2 protein.  Our studies further suggest that differences in the proteome of HDLCAD, in 
particular reduced HDL-associated clusterin and increased HDL-associated apoC-III, play an 
important role for altered activation of endothelial anti- and pro-apoptotic signaling pathways 
(Figure 8). 
 
Endothelial dysfunction and injury are thought to play an important role in initiation and 
progression of atherosclerotic CAD.
13-15
  Experimental studies have shown that atherosclerotic 
lesion-prone vascular regions such as bifurcations are characterized by high endothelial cell turn-
over,
16
 likely indicating an increased rate of endothelial cell apoptosis.
22
 Furthermore, coronary 
atherosclerotic plaque erosion with loss of an intact endothelial cell monolayer is frequently 
observed in patients with an acute coronary syndrome,
18, 19
 and areas of endothelial denudation 
may promote superficial thrombosis and progression of coronary atherosclerosis.
17, 36, 37
  The 
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capacity of HDL to inhibit endothelial cell apoptosis has therefore been suggested as an 
important potential anti-atherogenic property of HDL.
23-26
  
 
In the present study delipidated HDLHealthy exerted a more profound endothelial anti-apoptotic 
effect as compared to purified or recombinant apoA1 and reconstituted HDL, compatible with 
the concept that the HDL proteome is important for the regulation of endothelial anti-apoptotic 
pathways by HDL. Our HDL proteomics and gene ontology analysis suggested that changes in 
HDL-bound clusterin and apoC-III in HDLCAD could be relevant for altered effects on apoptosis. 
Subsequent validation experiments using HDL obtained by different preparative methods 
provided evidence that a reduced HDL-associated clusterin and an increased HDL-associated 
apoC-III content contribute importantly to altered effects of HDLCAD on endothelial apoptosis.  A 
previous study by Vaisar et al.
31
 on shotgun proteomics analysis of HDL observed a trend for a 
lower clusterin and a higher apoC-III content in HDL from patients with CAD according to the 
peptide index analysis, however, no validation experiments were performed.  The present study 
demonstrates for the first time that proteome remodeling in HDLCAD has direct implications on 
functional properties, i.e. vascular effects of HDL.  These findings point to a novel mechanism 
leading to altered vascular effects of HDL in patients with coronary disease, that at present is of 
particular interest, given the disappointing results of several clinical trials examining therapeutic 
strategies of HDL-cholesterol raising in these patients.  
  
Clusterin overexpression via adenovirus transfection has been suggested to render endothelial 
cells more resistant against TNF-α-induced apoptosis.38  In the present study, however, we have 
examined the effects of HDL-bound clusterin on endothelial apoptosis using extracellular 
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administration which represents a different setting as compared to overexpression in cultured 
cells. Notably, addition of clusterin alone did not result in an endothelial anti-apoptotic effect, 
that was only observed when clusterin was bound to HDL. Clusterin has been suggested to 
associate with apoA-I
39
 and paraoxonase-1.
40
 A recent study by Hoofnagle et al.
41
 observed that 
HDL-clusterin levels are reduced in insulin resistant men with a high body-mass-index. It was 
therefore speculated that a reduced HDL-clusterin-content may have functional implications for 
vascular effects of HDL. Of note, a potential anti-atherogenic role of clusterin has been 
supported by studies examining administration of a clusterin-peptide fragment to apoE-deficient 
mice and monkeys.
42
  In a study of 6 patients with coronary disease it has been observed that 
combined statin/niacin therapy may promote higher HDL-clusterin-levels in patients with 
coronary disease.
43
 Our present findings provide novel evidence that reduced HDL-clusterin-
levels are functionally important with respect to the impaired capacity of HDLCAD to exert 
endothelial anti-apoptotic effects.  
 
Serum clusterin levels have been reported to be increased in patients with developing coronary 
heart disease, or myocardial infarction, or type II diabetes
44
 and also in response to endotoxin and 
cytokines
45
. In the present study there was a trend towards increased clusterin-serum-levels. 
These observations further suggest that changes in the clusterin-content of HDLCAD are specific 
for HDL, and that the underlying cause is likely a reduced association of clusterin with HDL in 
patients with CAD rather than systemically reduced clusterin levels.  
 
We observed that HDL-associated clusterin activates via PI3K/Akt the endothelial anti-apoptotic 
protein Bcl-xL,  Bcl-xL belongs to the family of Bcl-2 proteins,
32
  has been proposed to be 
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regulated by Akt in tumor cells,
46
 and was reported as an important anti-apoptotic protein in 
endothelial and other cell types.
33
 The capacity of HDLHealthy to reduce endothelial apoptosis was 
not abolished when eNOS was inhibited, although the activation of PI3K/Akt was required for 
the anti-apoptotic activity of HDL. In line with this observation, a study by Suc et al. has 
suggested that the protective effect of HDL on endothelial cell survival  was not dependent on 
HDL-associated paraoxonase activity,
25
 that we have observed to be critical for the capacity of 
HDL to stimulate endothelial NO production.
10
  
 
In addition, our study demonstrates that increased levels of apoC-III associated with HDLCAD 
were responsible for activation of the pro-apoptotic p38-MAPK-signaling pathway in endothelial 
cells followed by increased expression of the pro-apoptotic protein tBid, a member of Bcl-2 
family of proteins.
34, 47
 Increased apoC-III levels have been associated with hypertriglyceridemia, 
metabolic syndrome and diabetes.
48-50
 ApoC-III inhibits the clearance of triglyceride-rich 
lipoproteins.
51
 A previous study has shown that LDL containing apoC-III was independently 
associated with an increased risk of CAD.
52
   Furthermore, a recent case-control study has 
suggested that HDL containing apoC-III is associated with a higher risk of future CHD.
53
 
Transfers of apoC-III between lipoprotein particles have been previously described.
54
 However, 
in the present study the apoC-III content was not only increased in the HDL fraction but also in 
the serum and the LDL/VLDL fraction of patients with CAD, suggesting an increased synthesis 
or a reduced clearance of apoC-III in patients with CAD.  
 
Of note, our findings do not exclude that HDL-associated lipids may also promote endothelial 
anti-apoptotic effects of HDL. In particular, HDL-associated lysosphingolipids have been 
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suggested to exert endothelial anti-apoptotic effects,
23
 although this has not been observed when 
sphingosine-1-phosphate (S1P) was added to reconstituted HDL.
26
 Interestingly, however, a 
recent study has examined the S1P content of HDL in patients with coronary disease and an 
acute coronary syndrome.
55
 Notably, in patients within the first hours of an acute coronary 
syndrome an increased S1P content of HDL was observed, suggesting that it would be unlikely 
that an altered S1P content could explain the loss of endothelial anti-apoptotic effects of HDL in 
these patients.
55
 
 
A recent study by Khera et al.
12
 supports the notion that HDL function may be more relevant as 
compared to HDL-cholesterol serum levels alone for development of coronary disease.  Khera et 
al. analyzed the cholesterol efflux capacity of apoB-depleted serum, that was lower in cases with 
coronary disease as compared to controls, independently of HDL-cholesterol levels.  The present 
study describes for the first time, that effects of HDL on endothelial cell apoptosis are markedly 
different between HDLHealthy and HDLCAD, that may limit the capacity of HDL to counteract 
clinical complications of atherosclerosis, since an impaired endothelial integrity has been 
suggested as an important mechanism promoting clinical complications of coronary disease. 
 
Study limitations. A potential limitation of the present study is the use of cardiovascular drugs 
in patients with CAD, but not in healthy subjects, that may impact on functional properties and 
composition of HDL. Previous studies have suggested that statin therapy may reduce apoC-III 
levels in plasma, HDL or apoB-containing lipoproteins.
56, 57
  In the present study most patients 
were on statin therapy, however, apoC-III levels in LDL/VLDL and HDL were still higher as 
compared to healthy subjects. While we cannot exclude that medical treatment in addition to the 
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underlying coronary disease may have impacted on altered HDL composition and function in 
patients with CAD, the present data are consistent with the notion that despite current medical 
therapy the function and composition of HDL remain abnormal as compared to healthy subjects. 
Another potential limitation of our study is the use of chloroform/methanol method for 
delipidation of HDL where we cannot exclude extraction of  hydrophobic proteins from HDL. 
However, since delipidated HDL still exerted a similar effect on endothelial apoptosis as 
compared to HDLHealthy before lipid extraction (Figure 3B), the anti-apoptotic protein 
components were likely largely present in the delipidated HDL protein fraction.      
 
In summary, our findings provide novel evidence that remodeling of the HDL proteome in 
patients with coronary disease has important functional implications with respect to effects of 
HDL on endothelial cell survival. In particular, we have observed that a reduced clusterin and 
increased apoC-III content in HDLCAD lead to an impaired effect of HDL on endothelial anti-
apoptotic pathways and an activation of pro-apoptotic-signaling in endothelial cells. These 
findings provide novel insights into mechanisms underlying altered vascular effects of HDL in 
patients with coronary disease.   
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FIGURE LEGENDS 
 
Figure 1 Effects of HDLHealthy, HDLsCAD or HDLACS on endothelial apoptosis in vitro. (A) 
The impact of HDLHealthy, HDLsCAD or HDLACS (50µg/ml based on protein measurement) on 
endothelial apoptosis was determined by annexin-V staining using FACS analysis after 16 hours 
of serum deprivation (n=20 per group) (B) Representative examples of flow cytometry analyses 
of annexin-V staining. Dark grey solid line: control cells for autofluoresence, Light grey dotted 
line: serum withdrawal, Red line: HDL-treated cells with serum withdrawal. (C) Endothelial 
apoptosis in the absence or presence of HDL (50µg/ml) was determined for the indicated time 
intervals following serum/growth factor deprivation. The dotted line represents buffer-treated 
cells with serum withdrawal. (D) Caspase-3 activity was measured from the lysate of endothelial 
cells treated with or without HDL (50µg/ml; n=20 per group). (E,F) Fluorescence microscopy of 
apoptotic endothelial cells stained with annexin-V-FITC. Number of annexin-V+ cells was 
counted per high power field (average values were taken from 5 hp-fields). (G) Effect of 
HDLHealthy, HDLsCAD or HDLACS (50µg/ml) on endothelial cell apoptosis induced by TNF-α as 
measured by annexin-V staining using FACS analysis. 
 
Figure 2 Effects of HDLHealthy, HDLsCAD or HDLACS on endothelial apoptosis in vivo. (A) 
Administration of HDLHealthy, but not HDLCAD (14mg HDL protein/kg body weight) to ApoE-/- 
mice via tail-vein injection reduced endothelial apoptosis as detected in the aorta after 24 hours 
(n=8-9 per group) as measured by co-staining of annexin-V+ and CD31+ using FACS analysis. 
(B) Representative flow cytometric analyses using anti-CD31-PE / annexin-V-APC co-staining 
of cells harvested from mouse aortas. (C) Immunofluorescence staining showed reduced active 
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caspase-3 staining of endothelial cells of mouse aortic sections after treatment with HDLHealthy, 
but not with HDLCAD.  (D,E)  TUNEL-FITC staining of mouse aortic sections co-stained with 
CD31-Texas-red. Number of TUNEL+ cells / Number of CD31+ cells was counted per high 
power field and the average was taken from 5 fields.     
 
Figure 3 Evaluation of the role of endothelial NO synthase and the effects of different HDL 
components (HDLHealthy) on endothelial apoptosis (A) HDLHealthy reduced endothelial 
apoptosis after inhibition of eNOS-mediated endothelial NO production by siRNA knockdown 
of eNOS or treatment with L-NAME (1 mM) (n=6-8 per group). Scr: scrambled. (B) Effects of 
HDLHealthy (50µg/ml), delipidated HDL (50µg/ml), apo A-1 (50µg/ml) or reconstituted HDL 
(50µg/ml) on endothelial apoptosis as measured by FACS analysis with annexin-V staining (n=6 
per group). Reconstituted HDL was prepared with the sodium cholate dialysis method using an 
apoA-I/POPC/cholesterol molar ratio of 1:80:10. (B) LC-ESI-MS/MS analysis of HDLHealthy and 
HDLCAD (n=6 per group).  Proteins identified were quantified using spectral index and data are 
presented as proteins reduced or enriched in HDLCAD. 
  
Figure 4 Role of HDL-associated clusterin for effects of HDLHealthy on endothelial anti-
apoptotic pathways. (A) MS/MS spectrum of a proteotypic peptide of clusterin. (B) 
Concentration of clusterin associated with HDLHealthy, HDLsCAD or HDLACS as quantified using 
ELISA. (C) HDLHealthy (50µg/ml) was pre-incubated with specific blocking antibody against 
clusterin (2-4µg/ml) and the effects of HDL on endothelial cell apoptosis induced by serum 
withdrawal were analyzed using annexin-V staining by FACS analysis, and (D) caspase-3 
activity assay. (E) Effect of the clusterin blocking antibody on the anti-apoptotic capacity of 
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HDLHealthy (50µg/ml) as examined in TNF-α stimulated endothelial cells. (F) Effects of HDLCAD 
(50µg/ml) on endothelial cell apoptosis in the presence of increasing concentrations of purified 
human clusterin (2.5-10µg/ml) were determined. (E) Effects of reconstituted HDL (50µg/ml)  in 
the absence or presence of clusterin on endothelial cell apoptosis were analyzed.  
 
Figure 5 Role of HDL-associated apoC-III for impaired endothelial anti-apoptotic effects of 
HDL in patients with CAD. (A) MS/MS spectrum of a proteotypic peptide of apoC-III. (B) The 
amount of apoC-III in HDLHealthy, HDLsCAD or HDLACS was quantified with ELISA. (C,D,E) 
HDLCAD (50µg/ml) was pre-incubated with specific blocking antibody against apoC-III (20µg/ml 
or 1:50 dilution) or isotype control and the effects of HDL on serum withdrawal induced- 
endothelial apoptosis were analyzed with annexin-V staining using FACS analysis and (F) 
caspase-3 activity measurement. (G,H,I) Effects of HDLCAD pre-incubated with a specific 
blocking antibody against apoC-III or isotype control on TNF-α-induced-endothelial apoptosis 
were analyzed with annexin-V staining using FACS analysis. (J) Effects of HDLHealthy (50µg/ml) 
on endothelial cell apoptosis in the presence of purified human apoC-III (5µg/ml).     
 
Figure 6 Activation of the endothelial anti-apoptotic signaling pathways by HDLHealthy. (A) 
Pre-treatment of endothelial cells with PI3K inhibitors, wortmannin (100nM) or LY294002 
(50µM) reversed the anti-apoptotic effects of HDLHealthy (50µg/ml). (B) Effects of HDLHealthy, 
HDLsCAD or HDLACS (50µg/ml) on the expression of endothelial Bcl-xL expression and (C) 
endothelial tBid expression  were assessed by western blot analysis (n=6 per group). (D) Effects 
of HDLHealthy (50µg/ml) on Bcl-xL expression in HAECs pre-treated with PI3K inhibitor as 
analyzed by western blot analysis. (E) Effects of HDLHealthy pre-incubated with specific blocking 
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antibody against clusterin (4µg/ml) on the phosphorylation of Akt at Ser473, (F) Bcl-xL 
expression (n=6 per group), as detected by western blot analysis. 
 
Figure 7 Stimulation of the endothelial pro-apoptotic signaling pathways by HDLCAD. (A) 
Effects of HDLHealthy and HDLCAD on phosphorylation of MAPK p38 were analyzed by western 
blot analysis (n=8-10 per group). (B) Effects of HDLCAD on endothelial tBid expression pre-
incubated with SB203580 (10µM). (C) Effects of HDLCAD pre-incubated with specific blocking 
antibody against apoC-III on the phosphorylation of MAPK p38, (D) tBid expression (n=6-8 per 
group), as detected by western blot analysis.              
 
Figure 8 Summary of major findings of the study. HDL proteome remodeling in CAD leads 
to altered effects on endothelial anti-apoptotic and pro-apoptotic pathways. HDLHealthy  carries 
higher amounts of clusterin, that upon induction of apoptosis promotes activation of endothelial 
PI3K/Akt leading to increased expression of anti-apoptotic Bcl-xL. In CAD, the level of HDL-
associated clusterin is reduced, whereas HDL-associated apoC-III content is increased. HDL-
associated apoC-III activates MAPK signaling via phosphorylation of p38 leading to increased 
activation of pro-apoptotic tBid. Our findings therefore suggest that  HDL proteome alterations 
in CAD have implications for the function of HDL with respect to its effects on endothelial 
integrity and survival. 
